Urothelial Cancer After Renal Transplantation: An Update

Chiang, Yang‐Jen; Yang, Pei-Shan; Wang, Hsu-Han; Lin, Kuo-Jen; Liu, K.-L.; Chu, Shih-Ming; Hsieh, Ching‐Hua

doi:10.1016/j.transproceed.2011.12.073

Cited by 25 publications

(20 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chiang et al [12] in a prospective analysis of 22 cases of BC in RTRs found a complete female predominance of the disease (54.3%). On the other hand, Wu et al [13] in a multivariate analysis found that female sex was an independent risk factor for TCC with a hazards ratio of 2.9 for incidence (p < 0.05).…”

Section: Discussionmentioning

confidence: 97%

De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study

et al. 2018

View full text Add to dashboard Cite

Background and Objectives: Renal transplant recipients (RTRs) have a 2- to 7-fold risk of developing a neoplasm compared to general population. Bladder urothelial neoplasms in this cohort has an incidence of 0.4–2%. Many reports describe a more aggressive behavior. The objective of this study is to describe oncologic characteristics of bladder urothelial neoplasms in RTRs and to evaluate its recurrence, progression, and survival rates. Methods: A retrospective multicentered study was performed evaluating all de novo bladder urothelial neoplasms cases in RTRs from 1988 to 2014. Descriptive statistical analysis and evaluation of recurrence, progression, and survival rates were performed. Results: A total of 28 de novo bladder transitional cell carcinomas (TCCs) were identified (incidence rate 0.64%). Cancer-specific survival rates were 100, 75, and 70% after 1, 5, and 10 years, respectively. Age at diagnosis superior to 60 years was found to be a statistically significant variable for recurrence risk. Progression rate was 14%. Presence of CIS was significantly associated with progression. All cancer-specific deaths were in the high-risk group and all were progressions from non-muscle invasive to muscle invasive bladder cancer. Conclusions: Bladder urothelial neoplasms following renal transplant is associated with a trend toward worst prognosis. Early aggressive treatments, such as early radical cystectomy, might be advisable to reduce cancer-specific deaths.

show abstract

Section: Discussionmentioning

confidence: 97%

De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…L'insuffisance rénale chronique (IRC) et la greffe rénale sont avancées comme facteur de survenue d'une TVES. Cependant, la surincidence liée à ces deux facteurs n'est rapportée que dans la population asiatique (Chine et Taiwan) [43,44]. La recherche spécifique d'une néphropathie à l'acide aristolochique (abordée ci après) n'est pas réalisée dans ces études, limitant les conclusions des auteurs sur le rôle de l'IRC en général et de la greffe.…”

Section: Autresunclassified

“…2). Cette intoxication toucherait dans son ensemble le continent asiatique avec une sous-estimation probable de cette étiologie d'origine médicinale dans la survenue de l'IRC et des TVES [43][44][45]49]. Une récente méta-analyse a établit un odd-ratio à 5,97 (IC à 95 % : 2,78-12,84) de développer une TVES en cas d'exposition à l'AcA [50].…”

Section: Néphropathie Des Balkans Et Aux Herbes Chinoisesunclassified

Épidémiologie et facteurs de risque des tumeurs de la voie excrétrice urinaire supérieure : revue de la littérature pour le rapport annuel de l’Association française d’urologie

Ouzzane

Rouprêt

Leon³

et al. 2014

Progrès en Urologie

View full text Add to dashboard Cite

“…China has experienced a similar trend. Indeed, according to our published data, urothelial carcinoma (UC) is the predominant malignancy among Chinese RT patients (6)(7)(8)(9). This is quite different from Western countries, in which non-melanoma skin cancer and post-transplantation lymphoproliferative disorder (PTLD) are the most common malignancies (10,11).…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center

Zhu

Xiao

Guo

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

The aim of this study was to assess the safety and efficacy of gemcitabine plus cisplatin/carboplatin (GC/GCa) chemotherapy in renal transplantation (RT) patients with urothelial carcinoma (UC). We reviewed the records of 12 RT patients with metastatic or locally advanced UC who received chemotherapy at our institution since January, 2013. All the patients received intravenous gemcitabine (800 mg/m) on days 1, 8 and 15, plus cisplatin (70 mg/m) or carboplatin (area under the curve = 5) on day 2, every 28 days. A total of 10 patients completed all the cycles, while 1 patient discontinued treatment due to disease progression and 1 patient discontinued due to non-medical reasons. In total, 12 patients received a median of four cycles of chemotherapy. The overall response rate was 50% (4/8 cases) in patients with measurable lesions. At the time of the study, 5 patients had succumbed to the disease (overall survival, 9.2 months), while 7 patients remained alive (follow-up time, 13.3 months). The most common toxicities were myelosuppression and gastrointestinal effects. Therefore, the GC/GCa regimen was found to be effective and tolerable in RT patients with UC. However, further studies involving more patients and control groups are required to confirm our results.

show abstract

Urothelial Cancer After Renal Transplantation: An Update

Cited by 25 publications

References 3 publications

De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study

De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study

Épidémiologie et facteurs de risque des tumeurs de la voie excrétrice urinaire supérieure : revue de la littérature pour le rapport annuel de l’Association française d’urologie

Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center

Contact Info

Product

Resources

About